Skip to main content

Strategic Diagnostics' Q2 Revenues Rise 5 Percent

NEW YORK (GenomeWeb news) – Strategic Diagnostics reported after the close of the market on Thursday that its second-quarter revenues increased 5 percent, and the firm cuts its net loss around 3 percent year over year.

The Newark, Del.-based firm brought in revenues of $6.9 million for the three-month period ended June 30, compared to revenues of $6.6 million for the second quarter of 2008. The company said that its revenues were positively impacted by a 16 percent increase in life science revenues and a 45 percent increase in sales of its Genomic Antibody Technology products.

Strategic Diagnostics trimmed its Q2 net loss to $734,000, or $.04 per share, from $1.1 million, or $.05 per share.

Its R&D spending decreased to $820,000 from $921,000, while its SG&A costs was trimmed to $3.5 million from $4.1 million.

Strategic Diagnostics finished the quarter with $6.2 million in cash and cash equivalents, plus $2.7 million in restricted cash.

Filed under

The Scan

Gap in COVAX Doses

BBC News reports that COVAX is experiencing a vaccine shortfall, as the Serum Institute of India has paused exports.

Sanofi, GSK Report Promising Results

The Wall Street Journal reports that the candidate SARS-CoV-2 vaccine from Sanofi and GlaxoSmithKline has had encouraging early results.

Influence of Luck

The New York Times examines how the US avoided variant-fueled increases in COVID-19 cases.

PLOS Papers on Retina GWAS, Hantaan Virus, COVID-19 Phenome-Wide Association Study

In PLOS this week: genome-wide association study of retinal morphology, analysis of hantaan virus found in a mouse, and more.